There was a significant decrease in the abundance of kallistatin (log2FC −0.13, p = 0.04), a serine proteinase inhibitor that some studies suggest is a biomarker for microvascular complications in diabetes patients [18]. This evidence concerns the gene SERPINA4 and diabetes mellitus.